2022
DOI: 10.3390/ijms23137357
|View full text |Cite
|
Sign up to set email alerts
|

Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients

Abstract: We investigated whether HLA class II eplet mismatch was related to dnDSA development and analyzed its combined impact with tacrolimus levels for kidney transplantation outcomes. A total of 347 kidney transplants were included. HLA Matchmaker was used for the single molecular eplet, total eplet, antibody (Ab)-verified eplet mismatch analyses, and Ab-verified single molecular analysis to identify HLA-DR/DQ molecular thresholds for the risk of dnDSA development. A time-weighted tacrolimus trough level (TAC-C0) of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 49 publications
0
1
0
Order By: Relevance
“…Eplet mismatch clearly has a role in risk stratification of transplant recipients during the post-operative period. Wiebe et al (105) demonstrated that patients with a lower eplet mismatch burden are better able to tolerate lower tacrolimus troughs without developing DSA, a finding that has been reproduced in multiple independent cohorts (106,107). As these studies reinforce, understanding of eplet mismatch burden will enable personalization of immunosuppression reduction after transplantation.…”
Section: Epletsmentioning
confidence: 94%
“…Eplet mismatch clearly has a role in risk stratification of transplant recipients during the post-operative period. Wiebe et al (105) demonstrated that patients with a lower eplet mismatch burden are better able to tolerate lower tacrolimus troughs without developing DSA, a finding that has been reproduced in multiple independent cohorts (106,107). As these studies reinforce, understanding of eplet mismatch burden will enable personalization of immunosuppression reduction after transplantation.…”
Section: Epletsmentioning
confidence: 94%